Are GLP-1 Agonists More Than Just Anti-obesity Drugs?

By Emeran Mayer, MD

A recently published article in the journal, Nature Medicine, discusses a significant study on the effects of blockbuster obesity drugs like Ozempic, which are known as glucagon-like peptide 1 (GLP-1) receptor agonists.
All Blog Posts

CONTENT for MEMBERS ONLY

If you’re already a member, please log in to access our collection of articles.

New here? Join our community by selecting one of our free or paid membership options and start enjoying exclusive content today.

Login
Sign Up

Premium Articles

Already a Paid Member? Login to View This Content.

Login

New Here? Enjoy access to Dr. Mayer’s Premium Articles by signing up for one of our Paid Memberships. 

Membership Includes: 

  • Ask Me Anything (AMA) Access 
  • Premium Articles 
  • Access to our Recipe Hub 
  • E-Books & Exclusive Discounts
Sign Up


Premium article.

Previous Post:
A Gut Risk for Kids: Prenatal Antidepressants?
Next Post:
Sexism in Medicine